2013 parkinson's disease glutathione four authors doi Targeting Ferroptosis in Disease: Mechanisms and Emerging Therapeutic Strategies A review of the evidence
Description
Parra-Rivas, L

Current evidence supports continuous use for 812 weeks followed by a 4-week washout period to assess sustained metabolic improvements and prevent receptor downregulation

A.GagneM.MinochaR.LongS.et al

Cysteamine Cysteamine is a tyrosinase inhibitor, but it also has the added benefit of protecting skin from UV radiation
